Drug Profile
ACTR 087/rituximab - Cogent Biosciences
Alternative Names: ACTR 087/rituximab combination therapy; ACTR087 + rituximab - Cogent Biosciences; ACTR087 + rituximab combination therapy; CD16V-41BB-CD3ζ; Viral ACTR + rituximab - Cogent BiosciencesLatest Information Update: 04 Jul 2021
Price :
$50
*
At a glance
- Originator Unum Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; Monoclonal antibodies; T lymphocyte cell therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; B cell inhibitors; CD20 antigen inhibitors; Immunologic cytotoxicity; Immunostimulants; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-Hodgkin's lymphoma
Most Recent Events
- 12 Jan 2021 Cogent Biosciences terminates licensing agreement with National University of Singapore and St. Jude Children’s Research Hospital for development of ACTR constructs
- 05 Oct 2020 Unum Therapeutics is now called Cogent Biosciences
- 28 Apr 2020 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Combination therapy, Refractory metastatic disease, Second-line therapy or greater) in USA (Parenteral)